Sector News

Teva mulls $7B stock offering to help fund Allergan generics buy

October 21, 2015
Life sciences

Teva’s $40.5 billion deal for Allergan’s generics company is going to help Allergan pay down much of its dealmaking debt.

But in the meantime, the Israeli pharma needs some acquisition money of its own–and it’s reportedly planning to raise as much as $7 billion this year to help fund the transaction.

The generics giant will drum up the funds through a share sale, Bloomberg’s sources say. It’s rounded up four banks to underwrite the offering, which it may launch as soon as November. It may also choose to sell a smaller number of shares to keep from diluting its existing shares, and take on debt to round out the financing.

Teva and Allergan struck their accord back in July, with Teva agreeing to fork over cash and stock to maintain its place at the top of the generics market. The company arranged $33.75 billion in bridge financing with 10 banks, including a senior unsecured loan of as much as $27 billion and about $6.75 billion in equity bridge financing, the news service notes.

And Teva’s not alone, either. Pharma’s M&A wave has seen multiple companies issue sky-high amounts of debt to help fund their pickups. Allergan itself will be using the money it gets from Teva to pare down the debt from its formative $66 billion merger–Allergan plus Actavis–earlier this year.

Meanwhile, Teva and Allergan are expecting to close their deal in the first quarter of next year; in a bid for antitrust approval, Teva is considering selling off a portfolio of drugs in the Middle East that it acquired with Allergan’s other products, Bloomberg reports.

By Carly Helfand

Source: Fierce Pharma

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend